The effects of the combined a-and ,B-adrenoceptor blocking drug, labetalol, on the uptake of
Introduction
Labetalol, in addition to its a-and ,B-adrenoceptor blocking actions (Brittain & Levy, 1976) , is thought to block a cocaine-sensitive inactivation process for noradrenaline. This was inferred from experiments with anaesthetized dogs which showed that labetalol was a potent antagonist of phenylephrine-induced vasopressor responses but was a much weaker antagonist of noradrenaline-induced vasopressor responses; this difference was not apparent in animals pretreated with cocaine. It was suggested that inhibition of a cocaine-sensitive inactivation process for noradrenaline by labetalol resulted in an increase in the plasma concentration of noradrenaline attained after intravenous injection, thereby counteracting the a-adrenoceptor blockade produced by labetalol (Farmer, Ken- nedy, Levy & Marshall, 1972; Kennedy & Levy, 1975) .
There are two cocaine-sensitive sites for the inactivation of blood-borne noradrenaline, the peripheral vascular beds and the pulmonary vascular bed (Vane, 1969) . In the peripheral vascular beds, noradrenaline is taken up into adrenergic nerves by the uptake1 process, whereas in the pulmonary vascular bed, noradrenaline is removed by an extra-neuronal process. Both processes are inhibited by cocaine but they are distinguishable by differences in their sensitivity to other uptake inhibitors (Alabaster & Bakhle, 1973; Iwasawa & Gillis, 1974) .
Labetalol could increase plasma noradrenaline concentrations by inhibiting either the uptake1 process or the pulmonary uptake process or both. The experiments to be described were undertaken to determine whether labetalol is an inhibitor of uptake1. (Iversen & Langer, 1969 ).
Methods
The method described by Iversen & Langer (1969) was used with minor modifications. Vasa deferentia were removed from rats (body weight 200 to 400 g) and cut into segments measuring 5 mm by 0.5 mm. Groups of five slices were incubated, with shaking, at 37°C for 30 min in 2 ml of incubation medium of values for the inhibitors of noradrenaline uptake were calculated as described by Lineweaver & Burke (1934) and Dixon (1953) respectively.
The following drugs were used: ascorbic acid (Roche), cocaine hydrochloride (Macfarlan Smith), (0) Iversen & Langer (1969) . Cocaine (1 to 100 jg/ml) was a simple competitive inhibitor of the uptake of [3H]-(-)-noradrenaline (Figure 1) . The highest concentration of cocaine used (100 jig/ml)inhibited uptake by 93%.
Labetalol (3 to 30 gg/ml) (Figure 2) (1977) and Summers & Tillman (1977) recently came to a similar conclusion from their experiments with labetalol in the isolated blood-perfused spleen of the cat.
The inhibitory action of labetalol on uptake1 does not appear to be related to either its a-or ,B-adrenoceptor blocking actions since a variety of drugs with little or no a-or f3-adrenoceptor blocking activity may act as uptake inhibitors (Iversen, 1967a) and, conversely, potent a-or P-adrenoceptor blocking drugs can be devoid of uptake inhibitory activity (present experiments; Foo, Jowett & Stafford, 1968) . Furthermore, the adrenoceptor blocking and uptake1 inhibitory actions of labetalol occur over entirely different concentration ranges. Thus, the threshold concentrations for ,B-adrenoceptor blockade, aadrenoceptor blockade and inhibition of uptake1 are about 1 ng/ml, 10 ng/ml (Brittain & Levy, 1976) and 1000 ng/ml (present experiments) respectively.
The results of the present experiments could account, at least in part, for the difference in the ability of labetalol to antagonize pressor responses to phenylephrine and noradrenaline in the anaesthetized dog (see Introduction). At present we do not know whether labetalol is capable of blocking the cocainesensitive uptake process in the pulmonary vascular bed. Experiments are in progress to determine this and to determine whether the blood levels of noradrenaline attained during intravenous infusion are increased in the presence of labetalol, as would be predicted if the drug was preventing the inactivation of noradrenaline. In preliminary experiments in the anaesthetized dog we have shown that plasma concentrations of intravenously infused noradrenaline are increased in the presence of labetalol, 1 to 10 mg/kg intravenously (Kennedy & Levy, unpublished 
results).
Finally, in a clinical context, labetalol has been reported to increase levels of free urinary catecholamines in some patients (Harris & Richards, 1977) . Increased adrenergic activity in response to the fall in blood pressure caused by labetalol is a likely explanation. However, an uptake1 inhibitory action is an obvious additional possibility although extrapolation from the present results is difficult as uptake processes in different tissues are known to exhibit considerable differences in their sensitivity to inhibition by various drugs (Iversen, 1967b; Iversen & Langer, 1969 
